WVE — Wave Life Sciences Share Price
0.000.00%
Last trade - 00:00- $908.64m
- $614.43m
- $108.30m
- 17
- 11
- 70
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.34 | ||
| Price to Tang. Book | 4.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.76% | ||
| Return on Equity | -77.87% | ||
| Operating Margin | -101.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.08 | 40.96 | 3.65 | 113.31 | 108.3 | 70.12 | 69.26 | 46.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Directors
- Christian Henry NEC (53)
- Paul Bolno PRE (47)
- Kyle Moran CFO (50)
- Christopher Francis SVP (43)
- Chandra Vargeese CTO (59)
- Michael Panzara OTH (54)
- Gregory Verdine DRC
- Mark Corrigan IND (63)
- Peter Kolchinsky IND (45)
- Adrian Rawcliffe IND (49)
- Ken Takanashi IND (57)
- Aik Na Tan IND (50)
- Heidi Wagner IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 23rd, 2012
- Public Since
- November 11th, 2015
- No. of Shareholders
- 9
- No. of Employees
- 287
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 153,486,021
- Address
- 7 Straits View, 018936
- Web
- https://www.wavelifesciences.com/
- Phone
- +65 62363388
- Contact
- Kate Rausch
- Auditors
- KPMG LLP
Upcoming Events for WVE
WAVE Life Sciences Ltd Annual Shareholders Meeting
Q2 2025 WAVE Life Sciences Ltd Earnings Release
Similar to WVE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Wave Life Sciences share price?
As of Today at 24:04 UTC, shares in Wave Life Sciences are trading at $5.92. This share price information is delayed by 15 minutes.
How has the Wave Life Sciences share price performed this year?
Shares in Wave Life Sciences last closed at $5.92 and the price had moved by +23.59% over the past 365 days. In terms of relative price strength the Wave Life Sciences share price has outperformed the S&P500 Index by +16.21% over the past year.
What are the analyst and broker recommendations for Wave Life Sciences?
The overall consensus recommendation for Wave Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Wave Life Sciences dividend yield?
Wave Life Sciences does not currently pay a dividend.
Does Wave Life Sciences pay a dividend?
Wave Life Sciences does not currently pay a dividend.
When does Wave Life Sciences next pay dividends?
Wave Life Sciences does not currently pay a dividend.
How do I buy Wave Life Sciences shares?
To buy shares in Wave Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Wave Life Sciences?
As of the previous close price of $5.92, shares in Wave Life Sciences had a market capitalisation of $908.64m.
Where are Wave Life Sciences shares listed?
Here are the trading details for Wave Life Sciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: WVE
What kind of share is Wave Life Sciences?
Based on an overall assessment of its quality, value and momentum Wave Life Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Wave Life Sciences share price forecast for 2025?
The analyst consensus target price for shares in Wave Life Sciences is $22.73. That is 283.95% above the last closing price of $5.92.
Analysts covering Wave Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.99 for the next financial year.
Find out moreWhat is the trend in the Wave Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wave Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -57.15%.
As of the last closing price of $5.92, shares in Wave Life Sciences were trading -39.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Wave Life Sciences PE Ratio?
The Wave Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Wave Life Sciences?
Wave Life Sciences' management team is headed by:
- Christian Henry - NEC
- Paul Bolno - PRE
- Kyle Moran - CFO
- Christopher Francis - SVP
- Chandra Vargeese - CTO
- Michael Panzara - OTH
- Gregory Verdine - DRC
- Mark Corrigan - IND
- Peter Kolchinsky - IND
- Adrian Rawcliffe - IND
- Ken Takanashi - IND
- Aik Na Tan - IND
- Heidi Wagner - IND